Summit Therapeutics (SMMT) is a publicly traded Healthcare sector company. As of September 2, 2026, SMMT trades at $14.49 with a market cap of $11.30B and a P/E ratio of -9.93. SMMT moved +3.18% today. Year to date, SMMT is -19.18%; over the trailing twelve months it is -40.60%. Its 52-week range spans $12.07 to $36.91. Analyst consensus is buy with an average price target of $28.35. Rallies surfaces SMMT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Summit Therapeutics (SMMT) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. SMMT moved +3.18% today. Analyst consensus is buy.
| Metric | Value |
|---|---|
| Price | $14.49 |
| Market Cap | $11.30B |
| P/E Ratio | -9.93 |
| EPS | $-1.44 |
| Dividend Yield | 0.00% |
| 52-Week High | $36.91 |
| 52-Week Low | $12.07 |
| Volume | 2.67M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-1.08B |
| Gross Margin | 0.00% |
14 analysts cover SMMT: 0 strong buy, 8 buy, 6 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $28.35.